Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial

Cordonnier, Catherine; Labopin, Myriam; Robin, Christine; Ribaud, Patricia; Cabanne, Ludovic; Chadelat, C; Cesaro, Simone; Ljungman, Per

doi:10.1038/bmt.2015.42

Cited by 26 publications

(15 citation statements)

References 20 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only 15% reported receiving the vaccine pre‐HSCT as recommended, only 55% of survivors reported receiving the vaccine post‐HSCT, and those who experienced the disease were almost 10 years older than those who did not contract the disease (62 vs 53 years, P = 0.01). Vaccine underutilization, immunosenescence, and (where vaccination did occur) vaccine failure may be responsible‐a combination of increasing age of survivors and poor maintenance of specific immunity to pneumococcal disease among long‐term HSCT survivors . Similarly, in the case of pertussis, the vaccine was administered to 72% of post‐HSCT survivors, 2.9% reported the disease and those that did so were >10 years older than those that reported not having the disease (65 vs 54 years, P = 0.01)).…”

Section: Discussionmentioning

confidence: 99%

A survey of infectious diseases and vaccination uptake in long‐term hematopoietic stem cell transplant survivors in Australia

Dyer

Gilroy

Brice

et al. 2019

Transplant Infectious Dis

View full text Add to dashboard Cite

Background This cross‐sectional survey aimed to establish the prevalence of infectious diseases and vaccination uptake in long‐term allogeneic hematopoietic stem cell transplants (HSCT) survivors in New South Wales, in order to reduce long‐term post‐HSCT morbidity and mortality and enhance long‐term care. Patients and methods Hematopoietic stem cell transplants survivors aged over 18 years and transplanted between 2000‐2012 in New South Wales (NSW) were eligible to participate. Survivors self‐completed the Sydney Post BMT Study survey, FACT‐BMT (V4), Chronic Graft versus Host Disease (cGVHD) Activity Assessment Self Report, Lee Chronic GvHD Symptom Scale, DASS21, Post Traumatic Growth Inventory, and the Fear of Recurrence Scale. Results Of the 583 HSCT survivors contacted, 441 (78%) completed the survey. Respondents included 250 (57%) males and median age was 54 years (range 19‐79 years). The median age at the time of transplant was 49 years (Range: 17‐71), the median time since HSCT was 5 years (Range: 1‐14) and 69% had cGVHD. Collectively, 41.7% of survivors reported a vaccine preventable disease (VPD) with the most common being influenza‐like‐illness (38.4%), varicella zoster/shingles (27.9%), pap smear abnormalities (9.8%), pneumococcal disease (5.1%), and varicella zoster (chicken pox) (4.6%). Only 31.8% had received the full post‐HSCT vaccination schedule, and the majority (69.8%) of these had received the vaccines via their General Practitioner. cGVHD was not found to be a significant factor on multivariate analysis for those who were vaccinated. There was a trend toward lower vaccination rates in patients in a lower income strata. Conclusions Vaccinating post‐HSCT survivors to prevent infections and their consequences have an established role in post‐HSCT care. Improving rates of post‐HSCT vaccination should be a major priority for BMT units.

show abstract

Section: Discussionmentioning

confidence: 99%

A survey of infectious diseases and vaccination uptake in long‐term hematopoietic stem cell transplant survivors in Australia

Dyer

Gilroy

Brice

et al. 2019

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…103 Prevnar is more immunogenic than Pneumovax secondary to inducing more durable, T-cell dependent memory responses. 104,105 Unless a patient is severely immunocompromised, Prevnar should be started at 6 months post HCT for a total of three doses, each administered two months apart. 105,106 One dose of Pneumovax should be given 6 to 12 months after the last Prevnar dose.…”

Section: Bloodstream Infection Preventionmentioning

confidence: 99%

Bacterial bloodstream infections in the allogeneic hematopoietic cell transplant patient: new considerations for a persistent nemesis

Dandoy

Ardura

Papanicolaou

et al. 2017

Bone Marrow Transplant

View full text Add to dashboard Cite

Bacterial bloodstream infections (BSI) cause significant transplant-related morbidity and mortality following allogeneic hematopoietic cell transplantation (allo-HCT). This manuscript reviews the risk factors for and the bacterial pathogens causing BSIs in allo-HCT recipients in the contemporary transplant period. In addition, it offers insight into emerging resistant pathogens and reviews clinical management considerations to treat and strategies to prevent BSIs in allo-HCT patients.

show abstract

“…14 Furthermore, in 40% of allogeneic stem cell transplant patients, who received three doses of PCV7 and one dose of PPV23 after transplantation, antibody concentrations remained at a protective level (0.50 mg/ml) for 8-11 years. 15 In our data antibody concentrations in patients with CLL declined during the five years following a single dose of PCV7 for six serotypes and for all serotypes in healthy controls. The number of subjects was quite small, but no statistically significant difference was seen between these two groups in median antibody concentrations.…”

Section: Abstract Antibody Persistence; Chronic Lymphocytic Leukemia;mentioning

confidence: 46%

Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia

Lindström

Aittoniemi

Salmenniemi

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Patients with chronic lymphocytic leukemia (CLL) are at a high risk for infections caused by Streptococcus pneumoniae. A pneumococcal conjugate vaccine (PCV) can induce a significant antibody response for some CLL patients. In this study we investigated antibody persistence after PCV7 in patients with CLL. The study material comprised 24 patients with CLL and 8 immunocompetent controls. The median antibody concentrations five years after PCV7 were lower for six pneumococcal serotypes in patients with CLL compared to controls, but the difference was not statistically significant. Depending on the serotype, the percentage of the CLL patients with antibody levels suggested to provide protection against invasive pneumococcal disease (IPD) varied from 29 to 71% five years after vaccination. This data suggests that PCV could result in antibody persistence at least five years in CLL patients.

show abstract

Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial

Cited by 26 publications

References 20 publications

A survey of infectious diseases and vaccination uptake in long‐term hematopoietic stem cell transplant survivors in Australia

A survey of infectious diseases and vaccination uptake in long‐term hematopoietic stem cell transplant survivors in Australia

Bacterial bloodstream infections in the allogeneic hematopoietic cell transplant patient: new considerations for a persistent nemesis

Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia

Contact Info

Product

Resources

About